Challenge
A consortium of pharmaceutical companies and biotech research labs formed a collaborative R&D cluster to stay ahead of emerging technologies. One question on their agenda: how could quantum technology – both quantum computing and quantum sensing – impact drug discovery, molecular simulation, and genomic analysis over the next decade? The life sciences industry relies heavily on advanced computation (for example, simulating how a drug molecule interacts with a target protein, or analyzing massive genomic datasets for disease insights) and on cutting-edge sensing/imaging techniques. The consortium members recognized that quantum computing promised to solve certain computational chemistry problems much faster than classical computers, and quantum sensors could potentially offer unprecedented sensitivity in biomedical measurements. However, there was considerable uncertainty about the timeline and practicality of these advances. The challenge was to separate hype from reality and to create a quantum opportunity roadmap: identifying which use cases in drug discovery and genomics could benefit most from quantum advancements, when those benefits might materialize, and how to prepare for or experiment with the technology in the meantime.
Additionally, because these firms dealt with highly sensitive research data (proprietary compound designs, patient genomic information, etc.), the cluster was also concerned with the flip side of the quantum coin – the risk that future quantum decryption capabilities could compromise long-term confidentiality of their data. While exploring quantum’s potential to accelerate innovation, they needed to simultaneously ensure that today’s research data wouldn’t be vulnerable to “harvest now, decrypt later” threats.
How Applied Quantum Helped
We led the consortium through a comprehensive process to develop their quantum R&D strategy. Our approach had three main components: prioritizing quantum-enabled use cases, planning experiments and partnerships, and fortifying data security for the quantum era.
Use Case Identification and Prioritization: We started by mapping out a broad list of potential applications of quantum computing and sensing in pharma/biotech. We interviewed R&D heads and scientists across the member organizations to gather ideas and pain points. We considered possibilities ranging from quantum algorithms for simulating complex molecular interactions (to improve drug candidate screening) to quantum machine learning on genomic data and quantum-enhanced biomedical imaging. In total, over 20 potential use cases were identified. We then applied a prioritization framework, considering factors such as: potential impact (e.g., would this dramatically speed up a currently slow step in drug development or enable something previously impossible?), technical feasibility (how many qubits or what sensor sensitivity would be required and is that likely in the next 5-10 years?), and the organization’s ability to act (do we have the right data or experimental setup to try this?). Through workshops with the consortium members, we scored and ranked these ideas. A handful of high-priority use cases emerged. For example, one top use case was quantum-enhanced drug molecular simulation – using quantum computers to calculate properties of complex molecules or reaction pathways that are intractable for classical computation, potentially shortening the cycle of drug candidate optimization. Another was quantum-assisted genomic analytics – exploring whether quantum algorithms could help find patterns in multi-gene interactions or protein folding related to genetic diseases, which classical algorithms struggle with due to combinatorial complexity. These became focus areas for the next stage of strategy.
Experiment and Partnership Roadmap: For each high-priority use case, we helped the cluster outline an “experiment roadmap.” We identified what could be done in the short term (1-2 years) vs medium term (3-5+ years) to evaluate quantum tech on these problems. In the short term, many quantum computing benefits would have to be assessed via small-scale experiments or simulations, since current hardware might not yet outperform classical methods. We facilitated connections with quantum hardware and software providers: for instance, arranging for the consortium’s researchers to collaborate with a leading quantum computing company’s application lab on a proof-of-concept for molecular energy calculations of a target drug compound. We also recommended forming a partnership with a university quantum chemistry group to stay updated on algorithm advances. The roadmap included concrete milestones – for example, in the near term to use current quantum processors to estimate a drug molecule’s properties on a small scale and compare against classical simulations, and in the longer term (when hardware improves) to tackle more complex, real-world molecular models. Similarly, on the sensing side, we outlined pilots such as testing whether a quantum magnetometer could detect subtle biochemical reactions or whether quantum-enhanced imaging could improve tissue sample analysis. Importantly, our roadmap emphasized partnerships: no single company in the cluster would buy a quantum computer outright at this stage, so pooling resources to access quantum hardware through cloud services or joint research agreements was key.
Data Security Guidelines for Long-Term Quantum Risk: Parallel to the innovation side, we addressed the consortium’s concerns about protecting sensitive data against quantum-enabled threats. We conducted a cryptographic audit of the types of data being generated and stored in R&D: genomic databases, encrypted research archives, intellectual property filings, etc. We identified data with long confidentiality requirements – for example, patient genomic data might need privacy for many decades, or proprietary drug formulas that must remain secret through the drug’s patent life. For these, we developed guidelines to implement quantum-resistant security measures. This included migrating wherever possible to encryption algorithms and key lengths deemed safe against quantum attacks (for example, using AES-256 for data at rest), and beginning to plan for deploying post-quantum cryptographic algorithms (for secure data transmission and authentication) as they become standardized. We advised each organization to establish a “crypto-agility” plan: essentially to inventory current cryptographic tools and ensure they can be swiftly updated when new PQC libraries and protocols are ready. We also gave guidance on strong key management practices – such as using longer key lengths, rotating keys more frequently, and even employing quantum random number generators for critical key material – to add additional safety margins.
Outcome
By the end of our engagement, the pharma and biotech cluster had a clear and balanced quantum technology roadmap to guide both their research investments and security practices. On the opportunity side, they now have a shortlist of high-impact quantum use cases with actionable next steps. In fact, the consortium launched three small-scale quantum computing pilot projects as a direct follow-up. In one, a team of chemists and quantum scientists began working with a quantum computing platform to simulate a key reaction in an oncology drug project – an experiment aimed at validating whether today’s quantum algorithms could predict outcomes that were hard for classical models to capture. Early results from these pilots, while not yet outperforming classical methods, have been insightful (as one research lead noted, just seeing a quantum computer tackle their molecular model provided new perspectives on approaching drug design). These projects also built internal skills – more researchers across the companies are now conversant in quantum concepts and prepared to leverage these tools as they mature.
The cluster’s members also took concrete steps in forming strategic partnerships. Following our roadmap, they collectively forged a partnership with a leading quantum computing provider – gaining early access to new hardware for their experiments. They also started a joint fellowship with a nearby university, sponsoring PhD research on quantum algorithms for drug discovery to create a pipeline of talent and fresh ideas for the cluster. This collaborative approach, guided by the strategy, meant that instead of each company dabbling separately (and perhaps redundantly) in quantum research, they are pooling knowledge and resources to accelerate learning.
On the defensive side, the consortium has significantly improved its long-term security posture. Each member company conducted a review of their research data encryption as we recommended, and several have already upgraded their practices – for example, moving archival data to new storage encrypted with longer keys, and incorporating the upcoming NIST post-quantum standards into their IT procurement requirements. The quantum-security checklist has been adopted as part of the cluster’s R&D governance. For example, the consortium agreed to implement quantum-resistant secure links between their sites, so that collaborative research data in transit is safeguarded even against future decryption attempts.
In summary, our engagement equipped the pharma and biotech cluster with a forward-looking yet pragmatic quantum strategy. They are now actively exploring quantum computing and sensing where it counts, armed with a realistic view of timelines and partnerships to help them succeed. Simultaneously, they have shored up the confidentiality of their invaluable data assets against tomorrow’s threats. This dual approach – maximizing upside while managing downside – has positioned them as innovators who are both bold and responsible. As quantum technology evolves, these companies will be among the first in their industry ready to leverage it for scientific breakthroughs while keeping their sensitive information safe.
© 2025 Applied Quantum. All rights reserved